Stony Brook researchers developed the Nobel Prize-winning technology that led to the MRI, helped develop the technology for PET scans, created the technology for 3D virtual colonoscopies and discovered the cause of Lyme disease. They developed groundbreaking new medications such as ReoPro® (a drug used for cardiac angioplasty), Periostat® (a drug used for periodontal disease) and Xiaflex® (a drug used for Dupuytren’s disease). 

The School conducts $90 million in funded research annually, with National Institutes of Health (NIH) sponsored research programs in neurological diseases, cancer, cardiovascular disorders, biomedical imaging, regenerative medicine and infectious diseases, among other topics. 

A Medical and Research Translation (MART) building, which houses Stony Brook University Cancer Center, is scheduled to open in early 2019. There, researchers and clinicians will join forces to build the most comprehensive, integrated and unified team with one singular purpose: to investigate, discover and drive innovations in cancer treatment.